Developer docs
API playgroundTry for free, no card

Search company profiles

Imugene

Full company profile

uuid00057mp

Namestring
Imugene
Legal namestring
Imugene Limited
Websiteurl
imugene.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Imugene Limited (ASX: IMU) is a publicly-listed clinical-stage biotechnology company founded in 2013 and headquartered in Sydney, Australia, with operations in the United States and Europe. The company develops immunotherapies for cancer, with two core technology platforms: azer-cel, a cell therapy targeting blood cancers (specifically B-cell malignancies including lymphoma), which has demonstrated an 82% response rate in clinical trials and received FDA confirmation that Phase 1b data supports a Phase 3 registrational study; and onCARlytics (CF33-CD19), an oncolytic virus platform designed to enable a 'mark and kill' combination strategy when paired with CAR-T cell therapies for solid tumors.

The company's business model is pre-commercial: Imugene generates no product revenue and instead finances operations through equity raises and milestone-linked licensing arrangements. Notable funding events include a $53.9M round in September 2022, a $13M Precision BioSciences-led tranche in August 2023, a $3.25M Precision BioSciences tranche in September 2024, and a $8.6M raise in April 2026. Precision BioSciences is also the licensor of azer-cel, triggering an $8M milestone payment to Precision BioSciences in Q4 2025. In November 2025, Imugene entered a strategic collaboration with JW Therapeutics to evaluate onCARlytics combined with JW's Carteyva CD19 CAR-T in refractory solid tumors, including preclinical work and a Phase 1 trial in China.

Imugene's customer-facing surface is essentially absent — its end users are cancer patients treated within clinical trials, not paying customers. The company serves a horizontal use-case segmentation (blood cancer patients, solid tumor patients) and addresses unmet need where conventional therapies show limited efficacy. Management announced a 50% operating cost reduction initiative to extend runway through upcoming clinical milestones. The global oncolytic virus immunotherapy market is projected to grow from approximately $156.8M in 2024 to $429.1M by 2030, with a broader projection exceeding $5B by 2031, situating Imugene within an emerging but increasingly competitive space (over 100 companies, 110 drugs in development per third-party landscape reports).

Short descriptiontext

Imugene is a clinical-stage Australian biotech developing immuno-oncology therapies — azer-cel (cell therapy for blood cancers) and onCARlytics (oncolytic virus platform for solid tumors) — targeting cancer patients with limited treatment options.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
oncolytic virus immunotherapy, cell therapy oncology, Cancer immunotherapy pipeline, CAR-T combination therapy, Clinical stage biopharmaceutical
Industry2 codes
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer immunotherapy / oncology biopharmaceuticals
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1azer-cel
Description

Blood cancer immunotherapy cell therapy program targeting blood cancer

tipranks.com
+1 more record
Core offering1 text field

Imugene is a clinical-stage biotechnology company developing proprietary immunotherapies for cancer. Its core offerings are azer-cel, an allogeneic cell therapy for blood cancers such as lymphoma that achieved an 82% response rate in a Phase 1b trial, and onCARlytics (CF33-CD19), an oncolytic virus platform designed to be combined with CAR-T cell therapies to treat solid tumors through a 'mark and kill' approach. The company advances these candidates through in-house clinical development and strategic partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 82% response rate in lymphoma trial
+2 more records
Product overview1 text field

Imugene is a biotechnology company developing immunotherapies for cancer treatment. The company's product portfolio consists of oncolytic virus immunotherapies including onCARlytics (CF33-CD19) for solid tumors and azer-cel for blood cancers. Imugene's approach focuses on viral-based cancer therapies that can be combined with other treatment modalities like CAR-T cell therapies to enhance anti-tumor responses.

Product and service1 record
1azer-cel
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Imugene and JW Therapeutics announced a strategic collaboration to evaluate a combination therapy involving Imugene's onCARlytics oncolytic virus and JW's Carteyva CD19 CAR-T cell therapy for refractory solid tumors. The partnership includes preclinical studies and a Phase 1 trial in China, aiming to develop a novel 'mark and kill' treatment strategy. The collaboration leverages both companies' platforms to generate data and advance clinical development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CG Oncology develops cretostimogene grenadenorepvec, an oncolytic virus immunotherapy for bladder cancer (FDA-approved). Directly comparable as a clinical/commercial-stage oncolytic virus company targeting solid tumors with similar mechanism of action to Imugene's onCARlytics.

TypeDirect peer
Description

Replimune develops a pipeline of oncolytic virus therapies (RP1, RP2, RP3) for solid tumors, with a 'tumor plus immune system' combination strategy. Comparable as a pure-play oncolytic virus immunotherapy developer with combination-therapy focus similar to Imugene's CF33-CD19 platform.

TypeDirect peer
Description

Genelux is a clinical-stage biopharmaceutical company developing oncolytic virus immunotherapies (Olvi-Vec) for solid tumors. Directly comparable as a small-cap, clinical-stage oncolytic virus developer with similar therapeutic focus to Imugene.

TypeDirect peer
Description

Allogene is a clinical-stage company developing allogeneic (off-the-shelf) CAR-T cell therapies for hematologic malignancies and solid tumors. Comparable to Imugene's azer-cel program, which is also an allogeneic CAR-T (developed with Precision BioSciences' ARCUS platform) targeting B-cell lymphomas.

TypeBroad incumbent
Description

Amgen commercializes Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for melanoma. Relevant as the incumbent validating the oncolytic virus category and as a potential strategic acquirer given its oncology and bispecific T-cell engager expertise relevant to Imugene's combination strategy.

TypeEmerging player
Description

Precision BioSciences is the licensor of azer-cel's underlying ARCUS gene-editing technology and receives milestone payments from Imugene (company history). Comparable as an allogeneic CAR-T developer with a related platform technology, and a strategic counterparty to Imugene.

TypeRegional player
Description

JW Therapeutics is a China-based CAR-T cell therapy company with Carteyva (relmacabtagene autoleucel) approved for lymphoma. Direct strategic partner with Imugene for combination studies of onCARlytics + Carteyva in solid tumors in China.

TypeDirect peer
Description

Iovance develops autologous cell therapies for solid tumors and hematologic malignancies, including lifileucel (FDA-approved TIL therapy). Comparable as a clinical/commercial-stage cell therapy company targeting cancers with limited treatment options, similar to Imugene's lymphoma focus.

9Turnstone Biologics
TypeEmerging player
Description

Turnstone Biologics is a clinical-stage immuno-oncology company developing oncolytic virus-based immunotherapies (e.g., TILT-123) for solid tumors. Comparable as a smaller peer pursuing combination strategies using oncolytic viruses to enhance tumor-infiltrating immune responses.

TypeEmerging player
Description

Lokon Pharma is a privately held Swedish clinical-stage company developing oncolytic virus immunotherapies (e.g., LOAd703) for solid tumors. Comparable as a niche, emerging player in the oncolytic virus space with combination-therapy focus, similar to Imugene's approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Imugene

Cancer immunotherapy / oncology biopharmaceuticalsimugene.com

Imugene is a clinical-stage Australian biotech developing immuno-oncology therapies — azer-cel (cell therapy for blood cancers) and onCARlytics (oncolytic virus platform for solid tumors) — targeting cancer patients with limited treatment options.

What Imugene does

Imugene Limited (ASX: IMU) is a publicly-listed clinical-stage biotechnology company founded in 2013 and headquartered in Sydney, Australia, with operations in the United States and Europe. The company develops immunotherapies for cancer, with two core technology platforms: azer-cel, a cell therapy targeting blood cancers (specifically B-cell malignancies including lymphoma), which has demonstrated an 82% response rate in clinical trials and received FDA confirmation that Phase 1b data supports a Phase 3 registrational study; and onCARlytics (CF33-CD19), an oncolytic virus platform designed to enable a 'mark and kill' combination strategy when paired with CAR-T cell therapies for solid tumors.

The company's business model is pre-commercial: Imugene generates no product revenue and instead finances operations through equity raises and milestone-linked licensing arrangements. Notable funding events include a $53.9M round in September 2022, a $13M Precision BioSciences-led tranche in August 2023, a $3.25M Precision BioSciences tranche in September 2024, and a $8.6M raise in April 2026. Precision BioSciences is also the licensor of azer-cel, triggering an $8M milestone payment to Precision BioSciences in Q4 2025. In November 2025, Imugene entered a strategic collaboration with JW Therapeutics to evaluate onCARlytics combined with JW's Carteyva CD19 CAR-T in refractory solid tumors, including preclinical work and a Phase 1 trial in China.

Imugene's customer-facing surface is essentially absent — its end users are cancer patients treated within clinical trials, not paying customers. The company serves a horizontal use-case segmentation (blood cancer patients, solid tumor patients) and addresses unmet need where conventional therapies show limited efficacy. Management announced a 50% operating cost reduction initiative to extend runway through upcoming clinical milestones. The global oncolytic virus immunotherapy market is projected to grow from approximately $156.8M in 2024 to $429.1M by 2030, with a broader projection exceeding $5B by 2031, situating Imugene within an emerging but increasingly competitive space (over 100 companies, 110 drugs in development per third-party landscape reports).

Imugene firmographics

Firmographics
Name
Imugene
Legal name
Imugene Limited
Website
https://imugene.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Imugene is a clinical-stage Australian biotech developing immuno-oncology therapies — azer-cel (cell therapy for blood cancers) and onCARlytics (oncolytic virus platform for solid tumors) — targeting cancer patients with limited treatment options.
Ownership category
akta.pro rank

Imugene industry classification

Industry
Product category
Cancer immunotherapy / oncology biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Oncolytic virus immunotherapy
  • Cell therapy oncology
  • Cancer immunotherapy pipeline
  • CAR-T combination therapy
  • Clinical stage biopharmaceutical

Where Imugene is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Markets served

Imugene business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Imugene product offering

Product offering

Core offering

Imugene is a clinical-stage biotechnology company developing proprietary immunotherapies for cancer. Its core offerings are azer-cel, an allogeneic cell therapy for blood cancers such as lymphoma that achieved an 82% response rate in a Phase 1b trial, and onCARlytics (CF33-CD19), an oncolytic virus platform designed to be combined with CAR-T cell therapies to treat solid tumors through a 'mark and kill' approach. The company advances these candidates through in-house clinical development and strategic partnerships.

Product overview

Imugene is a biotechnology company developing immunotherapies for cancer treatment. The company's product portfolio consists of oncolytic virus immunotherapies including onCARlytics (CF33-CD19) for solid tumors and azer-cel for blood cancers. Imugene's approach focuses on viral-based cancer therapies that can be combined with other treatment modalities like CAR-T cell therapies to enhance anti-tumor responses.

Differentiator

Problem solved

Functional benefit

Brands

  • azer-cel: Blood cancer immunotherapy cell therapy program targeting blood cancer
  • onCARlytics

Products and services

  • azer-cel

Quantifiable outcome

  • 82% response rate in lymphoma trial
  • +2 more outcomes

Companies that use Imugene

Customer profile

Segments1 record

Ideal customer profiles1 record

Imugene technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Imugene partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • JW TherapeuticscoreStrategic or Co-development Partner · 1 November 2025Imugene and JW Therapeutics announced a strategic collaboration to evaluate a combination therapy involving Imugene's onCARlytics oncolytic virus and JW's Carteyva CD19 CAR-T cell therapy for refractory solid tumors. The partnership includes preclinical studies and a Phase 1 trial in China, aiming to develop a novel 'mark and kill' treatment strategy. The collaboration leverages both companies' platforms to generate data and advance clinical development.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Imugene competitors and assessment

Company assessment

Direct peers

  • CG Oncology: CG Oncology develops cretostimogene grenadenorepvec, an oncolytic virus immunotherapy for bladder cancer (FDA-approved). Directly comparable as a clinical/commercial-stage oncolytic virus company targeting solid tumors with similar mechanism of action to Imugene's onCARlytics.
  • Replimune Group: Replimune develops a pipeline of oncolytic virus therapies (RP1, RP2, RP3) for solid tumors, with a 'tumor plus immune system' combination strategy. Comparable as a pure-play oncolytic virus immunotherapy developer with combination-therapy focus similar to Imugene's CF33-CD19 platform.
  • Genelux Corporation: Genelux is a clinical-stage biopharmaceutical company developing oncolytic virus immunotherapies (Olvi-Vec) for solid tumors. Directly comparable as a small-cap, clinical-stage oncolytic virus developer with similar therapeutic focus to Imugene.
  • Allogene Therapeutics: Allogene is a clinical-stage company developing allogeneic (off-the-shelf) CAR-T cell therapies for hematologic malignancies and solid tumors. Comparable to Imugene's azer-cel program, which is also an allogeneic CAR-T (developed with Precision BioSciences' ARCUS platform) targeting B-cell lymphomas.
  • Iovance Biotherapeutics: Iovance develops autologous cell therapies for solid tumors and hematologic malignancies, including lifileucel (FDA-approved TIL therapy). Comparable as a clinical/commercial-stage cell therapy company targeting cancers with limited treatment options, similar to Imugene's lymphoma focus.

Broad incumbents

  • Amgen: Amgen commercializes Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for melanoma. Relevant as the incumbent validating the oncolytic virus category and as a potential strategic acquirer given its oncology and bispecific T-cell engager expertise relevant to Imugene's combination strategy.

Emerging players

  • Precision BioSciences: Precision BioSciences is the licensor of azer-cel's underlying ARCUS gene-editing technology and receives milestone payments from Imugene (company history). Comparable as an allogeneic CAR-T developer with a related platform technology, and a strategic counterparty to Imugene.
  • Turnstone Biologics: Turnstone Biologics is a clinical-stage immuno-oncology company developing oncolytic virus-based immunotherapies (e.g., TILT-123) for solid tumors. Comparable as a smaller peer pursuing combination strategies using oncolytic viruses to enhance tumor-infiltrating immune responses.
  • Lokon Pharma: Lokon Pharma is a privately held Swedish clinical-stage company developing oncolytic virus immunotherapies (e.g., LOAd703) for solid tumors. Comparable as a niche, emerging player in the oncolytic virus space with combination-therapy focus, similar to Imugene's approach.

Regional players

  • JW Therapeutics: JW Therapeutics is a China-based CAR-T cell therapy company with Carteyva (relmacabtagene autoleucel) approved for lymphoma. Direct strategic partner with Imugene for combination studies of onCARlytics + Carteyva in solid tumors in China.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Imugene social profiles

Digital presence

Imugene financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Imugene leadership team

Management profile

Number of profiles

Profiles3 records

Imugene funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Imugene M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imugene

What does Imugene do?

Imugene is a clinical-stage biotechnology company developing proprietary immunotherapies for cancer. Its core offerings are azer-cel, an allogeneic cell therapy for blood cancers such as lymphoma that achieved an 82% response rate in a Phase 1b trial, and onCARlytics (CF33-CD19), an oncolytic virus platform designed to be combined with CAR-T cell therapies to treat solid tumors through a 'mark and kill' approach. The company advances these candidates through in-house clinical development and strategic partnerships.

Is Imugene a public or private company?

Imugene is a public company. It is classified as public and is currently operating.

When was Imugene founded?

Imugene was founded in 2013. It employs 11 to 50 people.

Where is Imugene based?

Imugene is headquartered in Sydney, Australia, in the Oceania region.

Who are Imugene's main competitors?

Direct peers on record are CG Oncology, Replimune Group, Genelux Corporation, Allogene Therapeutics and Iovance Biotherapeutics. Amgen is listed as a broad incumbent. Emerging players are Precision BioSciences, Turnstone Biologics and Lokon Pharma. JW Therapeutics is listed as a regional player.

Does Imugene have an API?

No public API is recorded for Imugene.

What industry is Imugene in?

Imugene's product category is Cancer immunotherapy / oncology biopharmaceuticals. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanPrecision Bio Q4 2025 profit, cash runway to 2028Precision BioSciences reported Q4 2025 net income of $20.1 million compared to a net loss of $17.8 million in Q4 2024, driven by revenue recognition from Novartis and Imugene agreements, while also reporting IND clearance for PBGENE-DMD and positive Phase 1 data for PBGENE-HBV. The company completed a $75 million financing in November 2025, extending its cash runway through 2028 to fund multiple clinical inflection points including the ELIMINATE-B trial and FUNCTION-DMD Phase 1/2 study. Fiscal year 2025 net loss was $45.7 million versus net income of $7.2 million in 2024, with total revenues declining to $34.3 million from $68.7 million due to reduced collaboration revenue.TipranksImugene Advances Azer-cel Program with FDA Support and Strategic PartnershipsImugene Limited has announced significant clinical progress in its azer-cel blood cancer immunotherapy program, supported by positive FDA feedback on its dosing regimen, which positions the company to advance to the next trial stage. The company has also formed a strategic collaboration with JW Therapeutics to leverage commercial CAR T infrastructure and expects to reduce operating costs by 50% in the coming year.MarketScreenerImugene's Phase 1b Study Date Confirmed by FDA to Support Phase 3 Registrational Study, Shares Jump 6%The FDA has confirmed the start date for Imugene's Phase 1b study, which is required to support its upcoming Phase 3 registrational trial. This regulatory milestone followed a period of uncertainty regarding the timeline for the company's clinical development program. The confirmation triggered an immediate positive market reaction, with Imugene's shares rising 6%.MarketScreenerImugene's Azer-Cel Hits 82% Response Rate in Lymphoma TrialImugene Limited announced that its Azer-Cel immunotherapy showed an 82% response rate in a lymphoma clinical trial. The company is developing various immunotherapies targeting cancer, including the off-the-shelf CAR T drug Azer-Cel.PR NewswireImugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid TumoursImugene Ltd and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a combination therapy pairing Imugene's onCARlytics (CF33-CD19) oncolytic virus with JW's CD19 CAR-T therapy Carteyva® for refractory solid tumors. The collaboration includes preclinical studies followed by a Phase 1 investigator-initiated trial to be conducted exclusively in China at premier CAR-T clinical centers. This first-in-class "mark and kill" strategy uses the oncolytic virus to induce CD19 expression on solid tumor cells, making them susceptible to targeting by CD19-directed CAR-T therapies.PR Newswire APACImugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid TumoursImugene Ltd and JW Therapeutics (Shanghai) have entered a strategic collaboration to evaluate a novel combination therapy pairing Imugene's onCARlytics (CF33-CD19) oncolytic virus with JW's Carteyva® CD19 CAR-T cell therapy for refractory solid tumors. The collaboration includes preclinical studies followed by a Phase 1 investigator-initiated trial to be conducted exclusively in China at premier CAR-T clinical centers. This approach uses the oncolytic virus to induce CD19 expression on tumor cells, making solid tumors susceptible to targeting by CD19 CAR-T therapies—a first-in-class "mark and kill" strategy.InsideprecisionmedicineTake II: Off-the-Shelf CAR T Shines in Relapsed/Refractory Lymphoma PatientsImugene reported Phase Ib trial data for its allogeneic CAR T therapy Azer-cel in relapsed/refractory diffuse large B-cell lymphoma, showing a 55% complete response rate and 75% overall response rate. The company plans to request an FDA End-of-Phase I meeting in Q4 2025 and initiate a Phase II trial in 2026.GlobeNewswireImugene and Kincell Bio Announce Strategic Manufacturing and Process Development PartnershipKincell Bio will acquire Imugene's North Carolina CGMP cell therapy manufacturing facility for up to $6M in upfront and milestone payments. Imugene will save $32M in staff costs and overhead over three years, reducing staff by 50% and extending cash runway to 2026. The partnership also outsources Azer-cel process development to Kincell.GlobeNewswireImugene and Kincell Bio Announce Strategic Manufacturing and Process Development PartnershipKincell Bio will acquire Imugene's North Carolina CGMP cell therapy manufacturing facility for up to $6M in upfront and milestone payments. Imugene will recognize $32M in cost savings and extend its cash runway to 2026. The partnership also transfers Azer-cel process development to Kincell.